Article in Science translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Xianliang RuiDivision of Pediatric Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA.ORCID 0009-0007-1219-4382
Lorenzo CagninDivision of Pediatric Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA.ORCID 0009-0007-1980-8340
Jennifer LaneDivision of Pediatric Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA.ORCID 0000-0001-8130-0176
Ulrike GerdemannDivision of Pediatric Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA.ORCID 0000-0002-3600-0366
Bruce R BlazarDivision of Pediatric Blood and Marrow Transplantation & Cellular Therapy, Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA.ORCID 0000-0002-9608-9841
Victor TkachevDivision of Pediatric Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA.ORCID 0000-0001-6011-0576
Leslie S KeanDivision of Pediatric Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA.ORCID 0000-0003-0475-3926
Funding
Transplant Tolerance in Non-Human PrimatesU19AI051731 · NIAID · UNIVERSITY OF WESTERN ONTARIO · PI ADAMS, ANDREW B · 2002 to 2022
$54.1M
Project 2: The New Era of Cellular Therapies For Lung Transplant ToleranceU19AI174967 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Joren C Madsen · 2023 to 2026
$18.8M
Single Cell Analysis and ImmunogeneticsP01HL158505 · NHLBI · DANA-FARBER CANCER INST · PI Corey S Cutler · 2022 to 2026
$15.3M
Novel Biologic Therapies for GVHDR01HL095791 · NHLBI · SEATTLE CHILDREN'S HOSPITAL · PI KEAN, LESLIE S · 2010 to 2025
$13.3M
Project 3: Enhanced Costimulation Blockade to Achieve Clinically Relevant Heart Allograft ToleranceP01HL158504 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI PIERSON, RICHARD N · 2021 to 2025
$12.1M
Research Training in Pulmonary Immunology and Allergy at MGHT32HL116275 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI David C Christiani, ANDREW D LUSTER · 2013 to 2026
$8.6M
In Vivo Prevention of Murine GVHDR37AI034495 · NIAID · UNIVERSITY OF MINNESOTA · PI Bruce R Blazar · 2017 to 2026
$5.4M
Nongenotoxic conditioning for gene therapy and allogeneic transplantation in Fanconi anemiaR01HL147324 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Bruce R Blazar, HANS-PETER KIEM · 2020 to 2026
$4.1M
Exploiting the VISTA Pathway to Prevent Acute GVHD and Control Steroid Refractory DiseaseR01HL155114 · NHLBI · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, NOELLE, RANDOLPH J. · 2021 to 2024
$2.7M
Mechanisms of Coronary Vasomotor ControlR01HL115114 · NHLBI · NORTHEAST OHIO MEDICAL UNIVERSITY · PI CHILIAN, WILLIAM M · 2013 to 2016
$1.4M
Understanding the role of Id2 in T cell differentiation and activation during GVHDF31HL156288 · NHLBI · HARVARD MEDICAL SCHOOL · PI INGERSOLL, KAYLEIGH · 2021 to 2023
Tissue-specific T cell immune responses play a critical role in maintaining organ health but can also drive immune pathology during both autoimmunity and alloimmunity. The mechanisms controlling intratissue T cell programming remain unclear. Here, we leveraged a nonhuman primate model of acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation to probe the biological underpinnings of tissue-specific alloimmune disease using a comprehensive systems immunology approach including multiparameter flow cytometry, population-based transcriptional profiling, and multiplexed single-cell RNA sequencing and TCR sequencing. Transcriptional profiling revealed substantial biological differences between T cells infiltrating the lung and liver during aGVHD. These included enrichment for transcriptional pathways controlling extracellular matrix remodeling and chemotaxis in the lung and enrichment for transcriptional pathways linked to nucleic acid metabolism and proliferation in the liver. Single-cell RNA sequencing and TCR sequencing substantiated divergent organ-specific transcriptional programing of tissue-infiltrating T cells, which was linked to clonal expansion, with expanded clones progressively enriched for
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Organ-specific microenvironments drive divergent T cell evolution in acute graft-versus-host disease. · full record | OpenQuestion